Kamada starts POC study of Glassia to treat GVHD Pharmaceutical Business Review The POC study is a Phase I/II trial of 24 patients with steroid-resistant GVHD following allogeneic bone-marrow stem cell transplant who will receive six to ten doses of intravenously delivered Glassia to determine safety, optimal dose and clinical ... |
